Oceania · News · The Courier-Mail

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

Published by The Courier-Mail · Australia 10 h ago

CSL (ASX:CSL) has ramped up its research and development efforts via a US$355 million ($515m)-plus drug development collab with private Swiss group Alentis Therapeutics.

Read the full article on The Courier-Mail Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.couriermail.com.au)

Also worth reading

The Guardian Australia

Peter and Maria were mourned by people who loved them. So how did they end up in unmarked communal graves?

The Age

The ‘loneliest place on Earth’ is a spectacular NZ spot most Australians miss

PerthNow

Congo boat collision: At least 30 dead and dozens still missing after vessels collide

iTWire

The best text to speech model, and what it costs you to hear it

Brisbane Times

Alex de Minaur books a spot in China Open final after semi-final twist

WAtoday

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

Share

Also worth reading

Peter and Maria were mourned by people who loved them. So how did they end up in unmarked communal graves?

The ‘loneliest place on Earth’ is a spectacular NZ spot most Australians miss

Congo boat collision: At least 30 dead and dozens still missing after vessels collide

The best text to speech model, and what it costs you to hear it

Alex de Minaur books a spot in China Open final after semi-final twist

Alex de Minaur books a spot in China Open final after semi-final twist